Peter Rossing

76.3k total citations · 27 hit papers
751 papers, 40.8k citations indexed

About

Peter Rossing is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Nephrology. According to data from OpenAlex, Peter Rossing has authored 751 papers receiving a total of 40.8k indexed citations (citations by other indexed papers that have themselves been cited), including 420 papers in Endocrinology, Diabetes and Metabolism, 293 papers in Cardiology and Cardiovascular Medicine and 216 papers in Nephrology. Recurrent topics in Peter Rossing's work include Diabetes Treatment and Management (245 papers), Chronic Kidney Disease and Diabetes (186 papers) and Blood Pressure and Hypertension Studies (146 papers). Peter Rossing is often cited by papers focused on Diabetes Treatment and Management (245 papers), Chronic Kidney Disease and Diabetes (186 papers) and Blood Pressure and Hypertension Studies (146 papers). Peter Rossing collaborates with scholars based in Denmark, United States and United Kingdom. Peter Rossing's co-authors include Lise Tarnow, Hans‐Henrik Parving, Melanie J. Davies, John B. Buse, Chantal Mathieu, Geltrude Mingrone, Απόστολος Τσάπας, Hiddo J.L. Heerspink, Frederik Persson and Deborah J. Wexler and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Peter Rossing

711 papers receiving 39.8k citations

Hit Papers

Dapagliflozin in Patients with Chron... 2012 2026 2016 2021 2020 2018 2020 2018 2012 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dapagliflozin in Patients with Chronic Kidney Disease
    2020 3.0k citations Hiddo J.L. Heerspink, Bergur V. Stefánsson et al. New England Journal of Medicine profile →
  2. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2018 2.6k citations Peter Rossing et al. profile →
  3. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
    2020 1.5k citations Peter Rossing et al. New England Journal of Medicine profile →
  4. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2018 1.1k citations Peter Rossing et al. profile →
  5. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
    2012 976 citations Hiddo J.L. Heerspink, Peter Rossing et al. profile →
  6. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2022 947 citations Peter Rossing et al. profile →
  7. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2019 834 citations Peter Rossing et al. profile →
  8. Diabetic kidney disease
    2015 793 citations Peter Rossing, Per‐Henrik Groop et al. profile →
  9. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
    2024 656 citations Vlado Perkovic, Katherine R. Tuttle et al. New England Journal of Medicine profile →
  10. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
    2022 631 citations Peter Rossing, Hiddo J.L. Heerspink et al. profile →
  11. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
    2021 578 citations Rajiv Agarwal, Peter Rossing et al. profile →
  12. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2022 532 citations Peter Rossing et al. profile →
  13. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
    2015 493 citations George L. Bakris, Ron T. Gansevoort et al. profile →
  14. Diabetes and Hypertension: A Position Statement by the American Diabetes Association
    2017 459 citations Peter Rossing, George L. Bakris et al. profile →
  15. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
    2022 386 citations Katherine R. Tuttle, Peter Rossing et al. profile →
  16. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
    2020 355 citations David C. Wheeler, Bergur V. Stefánsson et al. profile →
  17. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2019 352 citations Peter Rossing et al. profile →
  18. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
    2016 328 citations Peter Gæde, Peter Rossing et al. profile →
  19. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
    2021 237 citations David C. Wheeler, Robert D. Toto et al. profile →
  20. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
    2022 167 citations Katherine R. Tuttle, Peter Rossing et al. profile →
  21. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
    2021 161 citations George L. Bakris, Thomas Idorn et al. profile →
  22. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
    2023 147 citations Peter Rossing, Florian M.M. Baeres et al. Nephrology Dialysis Transplantation profile →
  23. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
    2024 80 citations Naveed Sattar, John J.V. McMurray et al. profile →
  24. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
    2024 74 citations Johannes F.E. Mann, Peter Rossing et al. profile →
  25. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
    2024 50 citations Richard E. Pratley, Katherine R. Tuttle et al. Journal of the American College of Cardiology profile →
  26. Combination therapy for kidney disease in people with diabetes mellitus
    2024 45 citations Petter Bjornstad, Frederik Persson et al. profile →
  27. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
    2025 44 citations Rajiv Agarwal, Jennifer B. Green et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Rossing Denmark 88 23.0k 11.0k 10.7k 8.5k 7.4k 751 40.8k
Mark E. Cooper Australia 109 17.9k 0.8× 13.2k 1.2× 12.7k 1.2× 11.6k 1.4× 5.9k 0.8× 514 48.8k
Christoph Wanner Germany 90 17.9k 0.8× 14.1k 1.3× 8.4k 0.8× 9.5k 1.1× 11.8k 1.6× 716 46.4k
Hiddo J.L. Heerspink Netherlands 81 16.2k 0.7× 10.9k 1.0× 6.6k 0.6× 6.1k 0.7× 6.7k 0.9× 599 29.2k
Johannes F.E. Mann Germany 66 13.9k 0.6× 9.3k 0.8× 10.5k 1.0× 5.1k 0.6× 6.1k 0.8× 277 30.0k
Vlado Perkovic Australia 82 16.0k 0.7× 8.9k 0.8× 8.5k 0.8× 5.8k 0.7× 8.0k 1.1× 406 30.9k
Silvio E. Inzucchi United States 85 32.3k 1.4× 2.8k 0.3× 9.2k 0.9× 13.6k 1.6× 12.0k 1.6× 416 44.4k
Eberhard Ritz Germany 97 9.4k 0.4× 19.5k 1.8× 13.8k 1.3× 6.5k 0.8× 6.2k 0.8× 934 44.8k
James R. Sowers United States 95 14.8k 0.6× 3.3k 0.3× 15.6k 1.5× 10.0k 1.2× 6.4k 0.9× 689 42.7k
Itamar Raz Israel 67 15.2k 0.7× 3.0k 0.3× 6.4k 0.6× 6.1k 0.7× 5.6k 0.8× 374 26.0k
Darren K. McGuire United States 85 25.8k 1.1× 2.0k 0.2× 14.1k 1.3× 9.8k 1.2× 10.7k 1.4× 461 40.0k

Countries citing papers authored by Peter Rossing

Since Specialization
Citations

This map shows the geographic impact of Peter Rossing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Rossing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Rossing more than expected).

Fields of papers citing papers by Peter Rossing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Rossing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Rossing. The network helps show where Peter Rossing may publish in the future.

Co-authorship network of co-authors of Peter Rossing

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Rossing. A scholar is included among the top collaborators of Peter Rossing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Rossing. Peter Rossing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hove, Jens Dahlgaard, Ulrik Dixen, Line Jee Hartmann Rasmussen, et al.. (2025). Association between interleukin-6, suPAR, and hsCRP with subclinical left ventricular dysfunction in type 1 diabetes: The Thousand & 1 study. Diabetes Research and Clinical Practice. 222. 112071–112071. 3 indexed citations
2.
Agarwal, Rajiv, Jennifer B. Green, Hiddo J.L. Heerspink, et al.. (2025). Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 393(6). 533–543. 44 indexed citations breakdown →
3.
4.
Pratley, Richard E., Katherine R. Tuttle, Peter Rossing, et al.. (2024). Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. Journal of the American College of Cardiology. 84(17). 1615–1628. 50 indexed citations breakdown →
5.
Perkovic, Vlado, Katherine R. Tuttle, Peter Rossing, et al.. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 391(2). 109–121. 656 indexed citations breakdown →
6.
Rossing, Peter, Tine W. Hansen, & Thomas Kümler. (2024). Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk. Diabetes Obesity and Metabolism. 26(S6). 13–21. 8 indexed citations
7.
Chertow, Glenn M., Hiddo J.L. Heerspink, Patrick B. Mark, et al.. (2024). Effects of Dapagliflozin in Patients with Membranous Nephropathy. SHILAP Revista de lepidopterología. 4(1). 137–145. 2 indexed citations
8.
Persson, Frederik, et al.. (2024). Bone mineral density and the risk of kidney disease in patients with type 1 diabetes. Journal of Diabetes and its Complications. 39(2). 108927–108927. 1 indexed citations
9.
McEwan, Phil, Jason A. Davis, Juan José García Sánchez, et al.. (2024). The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrology Dialysis Transplantation. 39(12). 2040–2047. 8 indexed citations
10.
Ahluwalia, Tarunveer S., Mie K. Eickhoff, Viktor Rotbain Curovic, et al.. (2023). Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease. Kidney International Reports. 9(2). 334–346. 5 indexed citations
11.
Vart, Priya, Jawad H. Butt, Niels Jongs, et al.. (2023). Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty. The Journals of Gerontology Series A. 79(2). 25 indexed citations
12.
Laursen, Jens Christian, Bryan Haddock, Christian Stevns Hansen, et al.. (2022). Kidney oxygenation, perfusion and blood flow in people with and without type 1 diabetes. Clinical Kidney Journal. 15(11). 2072–2080. 5 indexed citations
13.
Suvitaival, Tommi, Viktor Rotbain Curovic, Nete Tofte, et al.. (2022). Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetes. Cardiovascular Diabetology. 21(1). 135–135. 15 indexed citations
14.
Brandt, Niels, Philip Hasbak, Peter Gæde, et al.. (2022). Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial. Diabetes Obesity and Metabolism. 25(3). 844–855. 4 indexed citations
15.
Greenlaw, Nicola, James G. Boyle, Nish Chaturvedi, et al.. (2021). Metformin and carotid intima‐media thickness in never‐smokers with type 1 diabetes: The REMOVAL trial. Diabetes Obesity and Metabolism. 23(6). 1371–1378. 14 indexed citations
16.
Heerspink, Hiddo J.L., Bergur V. Stefánsson, Ricardo Correa‐Rotter, et al.. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 383(15). 1436–1446. 3050 indexed citations breakdown →
17.
Eickhoff, Mie K., Claire C. J. Dekkers, Gozewijn D. Laverman, et al.. (2019). Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors. Journal of Clinical Medicine. 8(6). 779–779. 71 indexed citations
18.
Petrie, John R., Nish Chaturvedi, Ian Ford, et al.. (2016). Metformin in adults with type 1 diabetes: D esign and methods of REducing with MetfOrmin V ascular A dverse L esions ( REMOVAL ): A n international multicentre trial. Diabetes Obesity and Metabolism. 19(4). 509–516. 27 indexed citations
19.
Zampetaki, Anna, Peter Willeit, Xiaoke Yin, et al.. (2015). Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. Diabetes. 65(1). 216–227. 95 indexed citations
20.
Jacobsen, Peter Karl, Lise Tarnow, Peter Rossing, et al.. (1995). The insertion/deletion polymorphism in the angiotensin I-converting enzyme gene predicts the progression of diabetic nephropathy during ACE inhibition in insulin dependent diabetic patients. Journal of the American Society of Nephrology. 6(3). 450. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark E. Cooper Breakdown of academic impact, for papers by Christoph Wanner Breakdown of academic impact, for papers by Hiddo J.L. Heerspink Breakdown of academic impact, for papers by Johannes F.E. Mann Breakdown of academic impact, for papers by Vlado Perkovic Breakdown of academic impact, for papers by Silvio E. Inzucchi Breakdown of academic impact, for papers by Eberhard Ritz Breakdown of academic impact, for papers by James R. Sowers Breakdown of academic impact, for papers by Itamar Raz Breakdown of academic impact, for papers by Darren K. McGuire
Rankless by CCL
2026